Beresford M W, Baildam E M
Institute of Child Health, Alder Hey Children's NHS Foundation Trust, University of Liverpool, Liverpool, UK.
Arch Dis Child Educ Pract Ed. 2009 Oct;94(5):151-6. doi: 10.1136/adc.2009.170860.
Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatic disease with significant long-term morbidity and mortality. Major advances have taken place in recent years in our understanding and the evidence base of JIA. The advent of biological therapies has opened a major new era in the medical management of JIA with recent trials published of etanercept, infliximab, adalimumab, abatacept, tocilizumab and anakinra. National and international collaborative clinical and research networks are ideally placed to enable future advances in the management of JIA and all paediatric rheumatic disorders. This review follows on from Part 1 of a review of recent advances in non-biological therapies in JIA, and focuses on the significant new advances in biological therapies in managing JIA.
幼年特发性关节炎（JIA）是最常见的儿童风湿性疾病，具有显著的长期发病率和死亡率。近年来，我们对JIA的认识和证据基础取得了重大进展。生物疗法的出现开启了JIA医学管理的一个重要新时代，最近已发表了关于依那西普、英夫利昔单抗、阿达木单抗、阿巴西普、托珠单抗和阿那白滞素的试验。国家和国际协作的临床及研究网络处于理想位置，能够推动JIA及所有儿童风湿性疾病管理方面的未来进展。本综述延续了JIA非生物疗法近期进展综述的第1部分，重点关注生物疗法在JIA管理方面的重大新进展。
